Buy-rated reports

588 tickers rated Buy
Ranks this page's recent reports by score.
O'Reilly Automotive, Inc.
ORLY·Consumer Discretionary
A ★★★★Buy
Current$89.05
Target$110.00
Return+23.5%
Aug 1, 2026

Riding the massive tailwind of an aging vehicle fleet nationwide, it is devouring the market with an invincible hub-and-spoke logistics network, though the 28x multiple tax and second-half cost pressures serve as short-term speed bumps.

Score
85
Robinhood Markets, Inc.
HOOD·Financials
A ★★★★Buy
Current$86.56
Target$120.00
Return+38.6%
Aug 1, 2026

Robinhood has successfully transitioned from a single-product retail brokerage into a highly diversified financial ecosystem capable of absorbing the immense intergenerational wealth transfer through its TradePMR RIA acquisition and explosive prediction market scaling.

Score
85
American Tower Corporation
AMT·Real Estate
A ★★★★Buy
Current$174.46
Target$216.06
Return+23.8%
Aug 1, 2026

Riding the AI infrastructure wave through CoreSite and entering a mechanical AFFO re-acceleration in 2027 makes the stock a coiled spring, though high leverage and emerging market FX headwinds demand patience.

Score
87
General Dynamics Corporation
GD·Industrials
A ★★★★Buy
Current$386.75
Target$420.00
Return+8.6%
Aug 1, 2026

The unassailable defense monopoly of nuclear shipbuilding is perfectly paired with accelerating, high-margin Gulfstream commercial aerospace deliveries, though constrained slightly by a historically elevated valuation multiple.

Score
89
Deutsche Bank Aktiengesellschaft
DB·Financials
A ★★★★Buy
Current$37.03
Target$45.65
Return+23.3%
Aug 1, 2026

Deutsche Bank is a vastly underpriced, highly profitable compounder executing massive 60% capital payouts, though its valuation rerating remains tethered to the containment of US commercial real estate risks and looming European regulatory capital shifts.

Score
89
Biogen Inc.
BIIB·Healthcare
A ★★★★Buy
Current$207.93
Target$245.00
Return+17.8%
Aug 1, 2026

Biogen offers a fundamentally de-risked turnaround play trading at a cheap 12.98x forward P/E, driven by its high-margin Growth Portfolio definitively overtaking declining MS assets.

Score
85
SoFi Technologies, Inc.
SOFI·Financials
A ★★★★Buy
Current$15.30
Target$24.00
Return+56.9%
Aug 1, 2026

SoFi is a hyper-growth banking juggernaut compounding fee revenue and cheap deposits via its 'everything app,' though heavy uncollateralized lending exposure in a turbulent rate environment warrants vigilant risk monitoring.

Score
86
Tradeweb Markets Inc.
TW·Financials
A ★★★★Buy
Current$97.80
Target$129.00
Return+31.9%
Aug 1, 2026

Tradeweb's structural market share gains in electronic fixed-income trading promise secular growth, though near-term revenue misses and LSEG's majority voting control warrant careful multiple monitoring.

Score
88
Banco de Chile
BCH·Financials
A ★★★★Buy
Current$40.72
Target$45.60
Return+12.0%
Aug 1, 2026

Banco de Chile is an elite compounding machine protected by a low-cost deposit monopoly and fortress capital, though its volume growth remains heavily tethered to a sluggish Chilean macroeconomic recovery and normalizing inflation.

Score
88
Fomento Económico Mexicano, S.A.B. de C.V.
FMX·Consumer Staples
A ★★★★Buy
Current$129.30
Target$145.35
Return+12.4%
Aug 1, 2026

Expect immense shareholder returns and fintech monetization to drive multiple expansion, though aggressive Mexican labor reforms and currency volatility remain constant structural headwinds against operating margins.

Score
92
Ameren Corporation
AEE·Utilities
A ★★★★Buy
Current$109.97
Target$124.00
Return+12.8%
Aug 1, 2026

Ameren offers a highly secure 6-8% earnings growth trajectory supercharged by $25 billion in legally protected hyperscaler data center investments, though investors must navigate the persistent friction of state rate cases and continuous capital raising.

Score
89
GSK plc
GSK·Healthcare
A ★★★★Buy
Current$53.22
Target$67.48
Return+26.8%
Jul 31, 2026

GSK offers a compelling valuation disconnect, pairing double-digit core earnings growth and a rapidly accelerating oncology pipeline against lingering but heavily quantified Zantac litigation risks.

Score
92
S&P Global Inc.
SPGI·Financials
A ★★★★Buy
Current$419.64
Target$519.20
Return+23.7%
Jul 31, 2026

S&P Global offers unparalleled, high-margin exposure to global capital market expansion and passive investing inflows, though investors must monitor the risk of AI-driven headcount reductions eroding its terminal-subscription base.

Score
88
Centene Corporation
CNC·Healthcare
A ★★★★Buy
Current$60.84
Target$76.80
Return+26.2%
Jul 31, 2026

Centene offers a deep-value, massive cash-generating turnaround play driven by confirmed 2026 structural margin repair, constrained solely by the looming political threat of ACA subsidy expirations.

Score
88
Veralto Corporation
VLTO·Industrials
A ★★★★Buy
Current$98.83
Target$114.40
Return+15.8%
Jul 31, 2026

Veralto combines a highly defensive razor/razor-blade water quality business with an accelerating software-driven product identification segment, generating robust free cash flow to fuel a disciplined M&A compounding strategy while capitalizing on immense data center and regulatory tailwinds.

Score
94
Incyte Corporation
INCY·Healthcare
A ★★★★Buy
Current$122.98
Target$140.00
Return+13.8%
Jul 31, 2026

The explosive commercial success of Opzelura and an impregnable $4.5 billion cash fortress provide a massive safety margin, while the looming 2028 Jakafi patent cliff demands flawless Phase 3 clinical execution from the dermatology and mutCALR pipelines to secure the 2030 growth narrative.

Score
93
Omnicom Group Inc.
OMC·Communication Services
A ★★★★Buy
Current$82.58
Target$115.00
Return+39.3%
Jul 31, 2026

Omnicom is a massive, highly profitable marketing juggernaut trading at a distressed 7.7x forward P/E due to overblown IPG merger fears, offering investors accelerating organic growth and a $5 billion buyback shield against macroeconomic headwinds.

Score
93
NXP Semiconductors N.V.
NXPI·Technology
A ★★★★Buy
Current$245.16
Target$296.00
Return+20.7%
Jul 31, 2026

Riding the unstoppable secular wave of software-defined vehicles and edge AI with fortress-like profitability, though heavy reliance on the cyclical auto market and significant debt require vigilant monitoring.

Score
89
Visa Inc.
V·Financials
A ★★★★Buy
Current$368.73
Target$425.00
Return+15.3%
Jul 31, 2026

Visa leverages an impenetrable network moat and explosive 34% growth in Value-Added Services to drive mid-teens EPS compounding, easily overcoming transient regulatory routing and antitrust headline risks.

Score
91
Hudbay Minerals Inc.
HBM·Materials
A ★★★★Buy
Current$21.55
Target$33.21
Return+54.1%
Jul 30, 2026

Hudbay offers unparalleled operating leverage to copper and gold with negative cash costs and zero net debt, perfectly positioning it to fund its generational Copper World growth pipeline.

Score
92
CGI Inc.
GIB·Technology
A ★★★★Buy
Current$74.26
Target$95.00
Return+27.9%
Jul 31, 2026

CGI presents a compelling value opportunity, pairing a massive CAD 31.8 billion backlog and robust 16.3% adjusted EBIT margins with a depressed 12.4x P/E multiple, providing an asymmetric entry point despite near-term organic growth headwinds.

Score
92
Hilltop Holdings Inc.
HTH·Financials
A ★★★★Buy
Current$39.81
Target$45.30
Return+13.8%
Jul 30, 2026

Hilltop offers fortressed capital safety and highly accretive share buybacks driven by a booming Texas commercial bank, counterbalanced only by the cyclical drag of its struggling mortgage origination unit.

Score
85
Northwest Bancshares, Inc.
NWBI·Financials
A ★★★★Buy
Current$15.90
Target$18.00
Return+13.2%
Jul 30, 2026

Expect significant total return as Northwest Bancshares leverages its low-cost deposit moat to fund aggressive C&I loan growth and expand NIM, though investors must monitor emerging credit stress within its specialized healthcare and nursing home loan portfolio.

Score
93
HNI Corporation
HNI·Industrials
A ★★★★Buy
Current$44.10
Target$65.00
Return+47.4%
Jul 30, 2026

HNI's transformative $1.9 billion acquisition of Steelcase offers massive synergy potential and deep undervaluation, though integration execution risks require careful monitoring alongside macro housing headwinds.

Score
88